Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — Q1 2022/23 Earnings Presentation
10 slides from Coloplast A/s Class B's earnings presentation, 2022
Slide 1: Making life easier
Conference call presentation Q1 2022/23 Making life easier STRIVE25: SUSTAINABLE GROWTH LEADERSHIP
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Solid start of 2022/23, in line with expectations
NEW IMAGE Solid start of 2022/23, in line with expectations Organic Reported ROIC growth EBIT margin 7% 29% * * 20% ** *before special items of 13 million DKK related to the Atos Medical integration **after tax and before special items 3
Slide 4: Q1 2022/23 organic growth driven by a solid start in Chronic Care
Q1 2022/23 organic growth was driven by a solid start in Chronic Care with broad based growth across regions excluding China Q1 2022/23 revenue by business area Q1 2022/23 revenue by geography Business Reported revenue FY Organic growth Share of organic Geographic Reported revenue FY Organic growth
Slide 5: Q1 reported growth up 18%, due to Atos Medical and currency
Q1 reported growth was up 18%, ~11%-points above organic growth, due to the inclusion of Atos Medical and currency appreciation Q1 2022/23 Revenue development (DKKm) Q1 2022/23 highlights • Organic growth was 7% or DKK 353 million, driven by: 936m DKK • Solid start in Chronic Care across geographies
Slide 6: Reported EBIT margin of 29% in Q1, reflecting cost inflation
Reported EBIT margin of 29%* in Q1, reflecting an impact from cost inflation, increased level of commercial activity and amortisation costs Q1 2022/23 EBIT margin development before special items (%) Q1 2022/23 highlights • Gross margin was 68%, on par with last year (positive FX impact of 90 bps) •
Slide 7: Adj. FCF in Q1 was DKK 576 million
Adj. FCF in Q1 was DKK 576 million, negatively impacted by an increase in net working capital. NWC-to-sales still expected at 24% for the FY FCF development1 FCF development Comments Q1 2022/23 highlights • Free cash flow for Q1 2022/23 was an inflow of DKK 212 million compared to an inflow of DKK 9
Slide 8: FY 2022/23 guidance of 7-8% organic growth unchanged
FY 2022/23 guidance of 7-8% organic growth and an EBIT margin of 28-30%* unchanged Organic revenue growth 7-8% Reported revenue growth in DKK 9-10% Reported EBIT margin* 28-30% Effective tax rate Around 21% Capital expenditures Around 1.4 bn DKK *before special items related to the Atos Medical inte
Slide 9: FY 2022/23 guidance breakdown: negative impact from input cost increases
FY 2022/23 guidance breakdown: significant negative impact from input cost increases on EBIT margin Development since issue of FY guidance Revenue growth assumptions Key impacts on gross- and EBIT margin development in 2022/23 Positive Unchanged Negative 68.8 ILLUSTRATIVE Unchanged FY 2022/23 organi
Slide 10: Mission, values and vision
Mission Making life easier for people with intimate healthcare needs Values Closeness… to better understand Passion… to make a difference Respect and responsibility… to guide us Vision Setting the global standard for listening and responding